BeyondSpring/BYSI

$2.76

2.98%
-
1D1W1MYTD1YMAX

About BeyondSpring

BeyondSpring Inc. is a clinical-stage global biopharmaceutical company. The Company is focused on developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs. The Company operates through two segments: the Plinabulin pipeline and Targeted Protein Degradation (TPD) platform. Plinabulin is being developed as a pipeline in a drug in various cancer indications as a direct anti-cancer agent and to prevent chemotherapy-induced neutropenia (CIN). Plinabulin is a small molecule derived from a natural compound found in marine microorganisms. It is a selective immunomodulating microtubule-binding agent (SIMBA), which may provide multiple therapeutic opportunities. The TPD platform is utilizing molecular glue technology to develop therapeutic agents and discover and develop new chemical entities for the debilitating diseases and disorders. The Company is also developing three small-molecule immune agents.

Ticker

BYSI

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Lan Huang

Employees

35

Headquarters

Florham park, United States

BeyondSpring Metrics

BasicAdvanced
$116M
Market cap
-
P/E ratio
-$0.54
EPS
0.46
Beta
-
Dividend rate
$116M
0.45766
$4.00
$0.65
218K
2.315
-61.8%
-88.85%
66.423
29.61%
36.66%
113.47%

What the Analysts think about BeyondSpring

Analyst Ratings

Majority rating from 1 analysts.
Buy

Price Targets

Average projection from 1 analyst.
54.71% downside
High $1.25
Low $1.25
$2.76
Current price
$1.25
Average price target

BeyondSpring Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-1,235.29% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$1.7M
112.5%
Net income
-$21M
65.35%
Profit margin
-1,235.29%
-22.19%

BeyondSpring Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 25.33%
QuarterlyAnnual
Q1 21
Q2 21
Q3 21
Q1 22
Actual
-$0.44
-$0.49
-$0.47
-
Expected
-$0.54
-$0.33
-$0.38
$0.48
Surprise
-18.52%
50.31%
25.33%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for BeyondSpring stock?

BeyondSpring (BYSI) has a market cap of $116M as of May 29, 2024.

What is the P/E ratio for BeyondSpring stock?

The price to earnings (P/E) ratio for BeyondSpring (BYSI) stock is 0 as of May 29, 2024.

Does BeyondSpring stock pay dividends?

No, BeyondSpring (BYSI) stock does not pay dividends to its shareholders as of May 29, 2024.

When is the next BeyondSpring dividend payment date?

BeyondSpring (BYSI) stock does not pay dividends to its shareholders.

What is the beta indicator for BeyondSpring?

BeyondSpring (BYSI) has a beta rating of 0.46. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the BeyondSpring stock price target?

The target price for BeyondSpring (BYSI) stock is $1.25, which is 54.71% below the current price of $2.76. This is an average based on projections from 1 analyst, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell BeyondSpring stock

Buy or sell BeyondSpring stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing